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Objective:  Pharmacological  LXR  activation  has  anti-atherosclerotic  actions  in  animal  models.  Part  of  these
beneﬁcial  effects  may  be explained  by accelerated  reverse  cholesterol  transport  since  both  plasma  high
density  lipoprotein  (HDL)  cholesterol  and fecal  neutral  sterol  secretion  are  higher  upon  LXR  activation.
Mechanisms  underlying  these  LXR-mediated  effects  have  not  been  fully  elucidated.
Methods: We  investigated  the  roles  of  the  isoforms  LXR  and  LXR  and  the  HDL  cholesterol  uptake
receptor  SR-B1  in modulation  of cholesterol  metabolism  upon  treatment  of  mice  with  the  LXR  ligand
T0901317.
Results:  HDL  cholesterol  was  maximally  60% increased  in  a time-dependent  fashion  due  to  appearance
of  more  and  larger  HDL  particles.  Fecal  neutral  sterol  secretion  was  maximally  induced  after  1  week
treatment.  T0901317  treatment  induced  fecal  neutral  sterol  secretion  by  ∼300% in wild-type  but  not  in
Lxr  deﬁcient  mice.  Surprisingly,  LXR  activation  reduced  SR-B1  protein  amount  in  hepatic  membranes,
suggesting  that  this  might  contribute  to elevated  HDL  cholesterol.  However,  T0901317  still elevated
plasma  HDL  cholesterol  in Sr-b1  deﬁcient  mice,  suggesting  that  SR-B1  is not  the  only  step  involved  in
LXR-mediated  induction  of plasma  HDL  cholesterol.  In  addition,  SR-B1  is  not essential  for LXR-induced
cholesterol  removal  from  the  body.
Conclusion: Induction  of fecal  neutral  sterol  secretion  by T0901317  critically  depends  on  LXR  but  not
on  LXR.  LXR  activation  reduces  SR-B1  in  hepatic  membranes,  probably  partly  contributing  to  elevated
HDL  cholesterol.  SR-B1  is not  required  to  enhance  fecal  neutral  sterol  secretion.. Introduction
Liver X receptors (LXR) are nuclear receptors that are activated
y oxysterols, i.e., oxygenated cholesterol metabolites [1]. Two LXR
soforms have been identiﬁed. LXR (NR1H3) is mainly expressed
n the liver and to a lesser extent in intestine and adipose tissue,
Abbreviations: ABC, ATP binding cassette; ApoAI, apolipoprotein AI; FPLC, fast
rotein liquid chromatography; HDL, high density lipoprotein; LXR, liver X recep-
or; SR-B1, scavenger receptor-1B; SREBP-1c, sterol-regulatory element-binding
rotein-1c;  TICE, transintestinal cholesterol excretion.
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while LXR (NR1H2) is ubiquitously expressed [2,3]. From in vitro
and in vivo studies employing pharmacological LXR ligands like
T0901317 [4] it is evident that LXR ligands are potentially promis-
ing for treatment of cardiovascular diseases. Pharmacological LXR
activation reduces atherosclerotic plaque development in animal
models of atherosclerosis (reviewed in [4]). Plasma high density
lipoprotein (HDL) cholesterol concentrations were increased upon
pharmacological LXR activation [4] and it has therefore been pro-
posed that this treatment induces ‘classical’ reverse cholesterol
transport, i.e., the transport of cholesterol from peripheral tissues
(e.g., macrophages) via HDL to the liver. Recently, however, van
der Veen et al. [5] showed that the increase in fecal neutral sterol
secretion induced by LXR activation in mice was mainly due to stim-
ulation of transintestinal cholesterol excretion (TICE), i.e., the direct
transfer of cholesterol from the plasma across the intestinal wall
into the feces [6].
Open access under the Elsevier OA license.So  far, the mechanism(s) underlying the LXR-mediated increase
in plasma HDL cholesterol concentration and the associated
changes in HDL composition have not been fully elucidated. We [7]
and others [8,9] have shown that LXR activation by pharmacological
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eans results in the appearance of large HDL particles in mice.
n the present study, we therefore have evaluated the effects
f LXR activation for speciﬁc periods of time on plasma HDL-
holesterol metabolism and fecal neutral sterol output in relation
o the presence and activity of scavenger receptor B1 (SR-B1)
ince the plasma HDL cholesterol proﬁles of LXR agonist-treated
ild-type mice closely resemble those observed in non-treated
r-b1 deﬁcient mice [10]. In addition, we clariﬁed the respective
oles of the two LXR isoforms LXR and LXR in induction of
ecal neutral sterol secretion and TICE by employing Lxr  ˛ deﬁcient
ice.
. Materials and methods
.1. Animals and in vivo experimental procedures
All mice were housed in a light- and temperature-controlled
acility (lights on 6:30 AM–6:30 PM,  21 ◦C), were fed a standard
aboratory chow diet (RMH-B, Abdiets, Woerden, The Netherlands)
nd had free access to drinking water. Experimental procedures
ere approved by the Ethics Committees for Animal Experiments
f the University of Groningen.
To study the time-dependent effects of LXR activation, male
57Bl/6J mice (Charles River, L’Arbresle Cedex, France) received
tandard chow containing T0901317 (0.015%, w/w)  for 1 day,
 week or 2 weeks. Untreated controls received non-supplemented
aboratory chow. On the last treatment day, 4-h fasted (8–12 AM)
nimals were sacriﬁced by cardiac puncture under isoﬂurane anes-
hesia. Livers were quickly removed, freeze-clamped and stored
t −80 ◦C. Blood was centrifuged (4000 × g for 10 min  at 4 ◦C) and
lasma was stored at −20 ◦C. Feces were collected for 24 h prior to
ermination.
Cholesterol ﬂuxes were measured in male Lxr˛−/− mice and
heir wild-type littermates on a Sv129/OlaHsd C57Bl/6J mixed
ackground [11] as described previously [5,12].  In short, at start
f the 2-week T0901317 treatment period, mice received an intra-
enous dose of 0.3 mg  (0.73 mol) cholesterol-D7 dissolved in
ntralipid (20%, Fresenius Kabi, Den Bosch, The Netherlands) and
n oral dose of 0.6 mg  (1.535 mol) cholesterol-D5 dissolved in
edium-chain triglyceride oil. Blood spots were collected from the
ail on ﬁlter paper (Schleicher & Schuell No2992, ‘s Hertogenbosch,
he Netherlands) daily for 14 days. At the end of the 2 weeks treat-
ent, mice were anesthesized by intraperitoneal injection with
ypnorm (fentanyl/ﬂuanisone, 1 ml/kg) and Diazepam (10 mg/kg).
he gallbladder was cannulated and bile was collected for 30 min.
ubsequently, mice were sacriﬁced by cardiac puncture and the
iver and the small intestine were excised. Feces were collected for
8 h prior to termination. Cholesterol was extracted from the blood
pots for gas chromatography/mass spectrometry (GC/MS) analysis
s described previously [12]. Biliary bile acids were determined by
n enzymatic ﬂuorimetric assay [13]. Total cholesterol concentra-
ions in plasma and bile were determined by gas chromatography,
s described below.
To study the role of SR-B1 in LXR-mediated effects on
holesterol metabolism, untreated male Sr-b1−/− mice on a
57BL/6J background [14] were fasted for 4 h and blood was
ollected by retro-orbital bleeding. Feces were collected for
4 h prior to retro-orbital bleeding. Next, these mice were fed
he diet with 0.015% (w/w) T0901317 for 2 weeks. On the
ast treatment day, 4-h fasted (8–12 AM)  animals were sac-
iﬁced by cardiac puncture under isoﬂurane anesthesia. Livers
ere quickly removed, freeze-clamped and stored at −80 ◦C.
lood was centrifuged (4000 × g for 10 min  at 4 ◦C) and plasma
as stored at −20 ◦C. Feces were collected for 24 h prior to
ermination.sis 222 (2012) 382– 389 383
2.2. Plasma lipoprotein analysis
Plasma lipoproteins were separated by fast protein liquid
chromatography (FPLC) and the total cholesterol content of the col-
lected fractions was  determined using a commercially available kit
(Roche Diagnostics, Mannheim, Germany).
The FPLC fractions were diluted 1:1 with 2× SDS loading buffer
(100 mM Tris–chloride, pH 6.8; 4% SDS; 0.2% bromophenol blue;
20% glycerol; 200 mM dithiothreitol). To determine the apoA-I con-
tent, equal volumes of FPLC fractions in SDS loading buffer were
subjected to SDS-PAGE on a 26-wells 12.5% gel (Criterion, Bio-Rad).
ApoA-I was determined using an antibody against human apoA-I
raised in rabbit (Calbiochem, San Diego, CA). Finally, horseradish
peroxidase-conjugated anti-rabbit from donkey (Amersham Phar-
macia Bioscience, GE Healthcare) and SuperSignal West Pico
Chemiluminescent Substrate System (Pierce, Rockford, IL) were
used.
2.3. Hepatic gene expression analysis
Total liver RNA was isolated using the TRI Reagent method
(Sigma) according to manufacture’s protocol. Integrity and
concentration of RNA were determined with the Nanodrop spec-
trophotometer (NanoDropTM 1000 Spectrophotometer, Thermo
Scientiﬁc, Waltham, MA). cDNA was obtained using the reverse
transcription procedure with Moloney Murine Leukemia Virus-RT
(Sigma, St. Louis, MO)  with random primers according to the pro-
tocol of the manufacturer. cDNA levels were measured in real-time
quantitative PCR ampliﬁcation using an ABI PRISM 7700 sequence
detector (Applied Biosystems, Foster City, CA) against a calibration
curve of pooled cDNA solutions. Expression levels were normal-
ized for -actin levels. The sequences of the primers and probes
can be found on www.labpediatricsrug.nl and are deposited at
RTPrimerDB (www.rtprimerdb.org).
2.4. Fecal neutral sterol and bile acid contents
Collected feces were dried and homogenized. Fifty micro-
grams of dried feces were boiled in 1 mL  alkaline methanol (1 M
NaOH/methanol, 1:3 vol/vol) at 80 ◦C for 2 h. After cooling down,
the sample was  extracted three times with 3 ml petroleum-ether
to collect the neutral sterols. The remaining sample was diluted
1:9 with distilled water and this was used for bile acid isolation by
reversed phase (C18) solid phase extraction. The neutral sterols and
the bile acids were derivatized to the methyl ester-trimethylsilyl
derivatives for gas chromatographic analysis [15]. The prepared
fecal neutral sterol and fecal bile acid samples were determined by
capillary gas chromatography using an Agilent gas chromatograph
(HP 6890) equipped with a 25 m × 0.32 mm CP-Sil-19 fused silica
column (Varian B.V., Middelburg, The Netherlands) and a Flame
Ionization Detector.
2.5. Immunoblot analysis
Hepatic membrane fractions were prepared as described before
[16] and the protein concentrations were determined using the
BCA Protein Assay kit (Pierce). Individual samples were mixed with
loading buffer, heated for 5 min  at 96 ◦C and subjected to SDS-
PAGE. SR-B1 was determined using an antibody against mouse
SR-B1 raised in goat (Novus Biologicals, Littleton, CO), PDZK1 was
determined using an antibody against mouse PDZK1 raised in rab-
bit (Abcam, Cambridge, UK). As loading controls, the concentration
of the -subunit of the Na/K-ATPase was determined using an anti-
body against Na/K-ATPase raised in goat [17]. Finally, horseradish
peroxidase-conjugated anti-rabbit from donkey (Amersham Phar-
macia Bioscience) or horseradish peroxidase-conjugated anti-goat
384 A. Grefhorst et al. / Atherosclerosis 222 (2012) 382– 389
Fig. 1. Pharmacological LXR activation resulted in a time-dependent increase of plasma HDL cholesterol, mainly due to the appearance of large HDL particles. Hepatic gene
expression of Abca1 (A), Abcg1 (B), Abcg5 (C), Abcg8 (D), Apoe (E) and Pltp (F) in untreated C57BL/6J mice and C57BL/6J mice treated with the pharmacological LXR ligand
T0901317 for 1 day, 1 week or 2 weeks. G. Cholesterol FPLC proﬁles of untreated C57BL/6J mice and C57BL/6J mice treated with the pharmacological LXR ligand T0901317
for  1 day, 1 week, or 2 weeks. Inset: Area under the curve (AUC) of the cholesterol vs. fraction curve. H. Immunoblots of apoA-I in FPLC fractions of untreated C57BL/6J mice
and  C57BL/6J mice treated with the pharmacological LXR ligand T0901317 for 2 weeks. I. Hepatic gene expression of ApoAI in untreated C57BL/6J mice and C57BL/6J mice
treated with the pharmacological LXR ligand T0901317 for 1 day, 1 week or 2 weeks. Values are averages ± SD; n = 6; bars without similar symbols are signiﬁcantly different.
osclerosis 222 (2012) 382– 389 385
f
P
i
w
2
m
s
c
3
3
e
d
a
t
T
t
g
(
m
h
s
o
ﬂ
h
(
(
3
o
a
t
r
c
(
i
t
1
m
p
I
t
T
t
a
I
r
e
O
e
d
(
f
r
0
5
10
15
20
25
30
35
2 weeks1 week1 dayControl
0
1
2
3
4
2 weeks1 week1 dayControl
T0901317
T0901317
A
B
Fe
ca
ln
eu
tra
l s
te
ro
ls
(μ
m
ol
/2
4 
h)
Fe
ca
lb
ile
ac
id
s
(μ
m
ol
/2
4 
h)
a
a
b
b
a
a,b
b
b
Fig. 2. Pharmacological LXR activation induces fecal neutral sterol and bile acid
secretion. The 24-h fecal neutral sterol (A) and bile acid (B) secretion of untreatedA. Grefhorst et al. / Ather
rom donkey (Dako, Glostrup, Denmark) and SuperSignal West
ico Chemiluminescent Substrate System (Pierce) were used. The
mmunoblots were analyzed by densitometry using ImageJ soft-
are (http://imagej.nih.gov/ij/).
.6. Statistics
Differences between groups were tested using a general linear
odel with corrections for multiple comparisons; P < 0.05 was con-
idered signiﬁcant when two groups were compared; P < 0.008 was
onsidered signiﬁcant when four groups were compared.
. Results
.1. The effects of pharmacological LXR activation on hepatic
xpression of Abca1, Abcg1, Abcg5, and Abcg8 do not depend on
uration of treatment
To study the temporal effects of LXR activation on plasma
nd hepatic cholesterol concentrations, male C57BL/6J mice were
reated with the commonly used pharmacological LXR ligand
0901317 for 1 day, 1 week or 2 weeks. To assess efﬁcacy of the
reatment protocol, expression of some well-deﬁned LXR target
enes encoding for the ATP binding cassettes A1, G1, G5, and G8
ABCA1, ABCG1, ABCG5, and ABCG8), ApoE and PLTP was  deter-
ined. As expected, treatment of mice with T0901317 increased
epatic expression of all genes. Abcg1,  Abcg5 and Abcg8 expres-
ion all had a maximal induction already reached after one day
f LXR activation (Fig. 1B–D) while Abca1 expression (Fig. 1A)
uctuated throughout the treatment period. T0901317 induced
epatic Apoe expression with maximal effect after already 1 day
Fig. 1E) while Pltp is induced in a time-dependent manner
Fig. 1F).
.2. The appearance of large HDL particles but not the induction
f fecal neutral sterol secretion depends on the duration of LXR
ctivation
One day of T0901317 treatment did not affect plasma choles-
erol concentrations (Fig. 1G). Prolonged treatment, however,
esulted in elevated HDL and a time-dependent appearance of
holesterol in FPLC fractions preceding the ‘normal’ HDL peak
Fig. 1G), indicative for the presence of larger particles. This
ncrease in HDL cholesterol was reﬂected by the increased plasma
otal cholesterol concentrations that were 0.96, 1.11, 2.03 and
.84 mM in control, 1-day, 1-week and 2-week T0901317-treated
ice, respectively. We  checked whether the ‘extra’ cholesterol
eak represents large HDL by determining its apolipoprotein A-
 (apoA-I) protein content by immunoblotting. Fig. 1H shows
hat, indeed, in FPLC fractions collected from mice treated with
0901317 for 2 weeks, apoA-I was detectable in earlier frac-
ions compared to fractions collected from untreated mice. In
ddition, T0901317 treatment also increased the amount of apoA-
 in the ‘normal’ HDL fractions. Although T0901317 treatment
esulted in increased plasma apoA-I concentrations, ApoaI gene
xpression in the liver was not induced by T0901317 (Fig. 1I).
ne week of T0901317 even slightly reduced hepatic ApoaI
xpression.
Fecal bile acid secretion was not affected by T0901317 after oneay of treatment, but reached maximal induction after one week
Fig. 2). Similarly, one day T0901317 treatment also did not affect
ecal neutral sterol secretion, but both 1- and 2-week treatment
egimes resulted in a clear ∼4 fold induction (Fig. 2).C57BL/6J mice and C57BL/6J mice treated with the pharmacological LXR ligand
T0901317 for 1 day, 1 week, or 2 weeks. Values are averages ± SD; n = 6; bars without
similar symbols are signiﬁcantly different.
3.3. The effects of T0901317 on fecal sterol loss and TICE critically
depend on the presence of LXR˛
To determine the contribution of TICE to the enhanced neutral
fecal cholesterol secretion upon T0901317 treatment and to evalu-
ate its dependence on LXR, we  repeated the two-week T0901317
protocol in Lxr˛−/− mice and their wild-type littermates and com-
bined this with the TICE protocol as described previously [11,12].
The data presented in Fig. 3 show that the induction of plasma
cholesterol concentration, biliary cholesterol secretion, fecal neu-
tral sterol secretion, and TICE by T0901317 all critically depend on
the presence of LXR.
3.4. Pharmacological LXR activation reduces SR-B1 protein
amount in the hepatic membrane
The appearance of large HDL particles upon pharmacological
LXR activation resembles the phenotype of Sr-b1−/− mice [10]. Lit-
tle is known about SR-B1 regulation, yet, PDZK1 plays an important
role in stabilizing SR-B1 protein in membranes [18,19].  Pdzk1−/−
mice have a plasma cholesterol proﬁle comparable to that of Sr-
b1−/− mice [20]. To study the potential involvement of SR-B1 and/or
PDZK1 in the appearance of the large HDL upon LXR activation, we
determined their hepatic gene and membranous protein expres-
sion.
Hepatic Sr-b1 mRNA expression was  not affected by the LXR
agonist treatment (Fig. 4A). One day of T0901317 treatment did not
affect SR-B1 protein content in isolated membrane fractions (Fig. 4C
and D), but one and two  weeks of treatment resulted in a clear
reduction of the amounts of mature SR-B1 protein in membranes
and the appearance of a lower band in the immunoblot.
T0901317 treatment affected neither hepatic Pdzk1 gene
expression (Fig. 4B) nor appearance of the PDZK1 protein in
386 A. Grefhorst et al. / Atherosclerosis 222 (2012) 382– 389
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Fig. 3. Effects of pharmacological LXR activation by T0901317 on biliary and fecal neutral sterol secretion depends on the presence of LXR. Biliary cholesterol secretion
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oncentrations (F) of Lxr˛−/− mice and their wild-type littermates treated with or w
 = 4–6; bars without similar symbols are signiﬁcantly different.
epatic membranes after one and two weeks of pharmacological
XR activation (Fig. 4C).
.5. T0901317 enhances fecal neutral sterol secretion
ndependently of SR-B1
The reduced amount of SR-B1 protein in hepatic membranes
pon T0901317 treatment suggest that this might contribute to the
levated plasma HDL cholesterol. To test this, we treated Sr-b1−/−
ice with T0901317 for 14 days. Treatment of Sr-b1−/− mice with
he LXR agonist treatment raised the plasma cholesterol concentra-
ions (Fig. 5A; 3.98 vs. 5.00 mM  plasma total cholesterol, untreated
s. 2-week T0901317-treated mice) suggesting that the T0901317
nduced reduction of plasma membrane Sr-b1 is not the only rea-
on underlying the HDL increase in wild-type mice. Similarly to
ild-types (Fig. 2), T0901317 treatment of Sr-b1−/− mice enhanced
ecal neutral sterol secretion by 300% but did not affect fecal bile
cid secretion (Fig. 5B and C).
. Discussion
In this study we show for the ﬁrst time that sustained LXR acti-
ation by T0901317 affects homeostasis of the HDL receptor SR-BI
n mice. Although Sr-b1 gene expression levels were unaltered,
resence of SR-BI in the hepatic membranous pool reduced. SR-
1 is essential in hepatic uptake of HDL-derived cholesterol (ester)
21]. This novel observation suggests that the time-dependent raise
n plasma HDL cholesterol-concentrations with the appearance
f more and larger HDL particles is not only a consequence ofiliary bile acid secretion (D), fecal bile acid secretion (E) and plasma cholesterol
t the pharmacological LXR ligand T0901317 for 2 weeks. Values are averages ± SD;
enhanced ABCA1-mediated production [7,22] but also of impaired
SR-B1-mediated uptake. Interestingly, T0910137 treatment of Sr-
b1 deﬁcient mice also raised plasma HDL levels. This can probably
be explained by the fact that in the absence of HDL uptake, a
small increase in ABCA1 and ABCG1- induced peripheral choles-
terol efﬂux will have a relatively large effect on plasma cholesterol
concentrations. In wild-type mice, the decrease in hepatic SR-B1
protein upon T0901317 treatment coincided with enhanced fecal
neutral sterol secretion, strongly suggesting that SR-B1 mediated
hepatic HDL cholesterol uptake is not required for LXR-induced
fecal neutral sterol secretion. Indeed, pharmacological LXR activa-
tion also enhanced fecal neutral sterol secretion in Sr-b1−/− mice.
Prolonged activation of LXR induced all the phenotypical aspects
associated with enhanced RCT: elevated plasma HDL cholesterol
(Fig. 1C) and enhanced fecal neutral sterol secretion (Fig. 2), as has
repeatedly been shown before (see for review [4]). The enhanced
Apoe and Pltp expression might both have contributed to the
appearance of the larger HDL particles. Larger HDL is known to con-
tain ApoE and PLTP can catalyze the conversion of two  HDL particles
to one larger HDL particle and one small lipid-poor apoA-I parti-
cle, pre--HDL [23,24].  Until recently, elevated HDL and enhanced
fecal neutral sterol secretion upon LXR activation were thought to
be mechanistically linked, especially since they appeared together
with changes in gene transcription that are indicative for enhanced
macrophage-to-liver cholesterol ﬂux and subsequent conversion
of cholesterol into bile acids. In line with previous publications
[7,22,25], the present study also demonstrates that elevated plasma
HDL cholesterol concentrations and enhanced fecal neutral sterol
secretion are not linked to each other by deﬁnition.
A. Grefhorst et al. / Atherosclerosis 222 (2012) 382– 389 387
Fig. 4. Disturbed cellular distribution of SR-B1 protein in the liver and reduced PDZK1 protein of mice upon pharmacological LXR activation. A and B. Hepatic gene expression
of  Sr-b1 (A) and Pdzk1 (B) in untreated C57BL/6J mice and C57BL/6J mice treated with the pharmacological LXR ligand T0901317 for 1 day, 1 week or 2 weeks. Values
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sre  averages ± SD; n = 6. C. Immunoblot of SR-B1 and PDZK1 in hepatic membrane
igand  T0901317 for 1 day, 1 week, or 2 weeks. D. Density of the membranous full
verages  ± SD; n = 3; *P < 0.008.
In contrast to biliary bile acid secretion, biliary cholesterol
ecretion has been shown to be increased upon LXR activation
22] but, when extrapolated to daily secretion, this effect could
y no means explain the concomitant induction of fecal neu-
ral sterol secretion. Earlier studies already demonstrated that
XR-induced fecal neutral sterol secretion is only partly depen-
ent on biliary cholesterol secretion [26] and is mainly explained
y activation of a process referred to as transintestinal choles-
erol excretion or TICE [5]. In the current study, we  show for
he ﬁrst time that the effects of T0901317 on cholesterol secre-
ion critically depend on the presence of LXR. T0901317 did
ot at all stimulate biliary cholesterol secretion, fecal neutral
terol excretion or TICE in Lxra−/− mice (Fig. 3), thus indicating
hat LXR is not involved. Interestingly, intestine-speciﬁc acti-
ation of LXR has been shown to be anti-atherogenic despite
elatively modest induction of fecal neutral sterol secretion [27].
ince whole body LXR activation is associated with hepatic-speciﬁc
ide-effects like hepatic steatosis [7,28],  intestine-speciﬁc LXR-
ctivation might provide a better option for novel therapeutic
trategies.ntreated C57BL/6J mice and C57BL/6J mice treated with the pharmacological LXR
 and smaller SR-B1 vs. Na/K-ATPase calculated using ImageJ software. Values are
The T0901317-mediated reduction of SR-B1 protein in hep-
atic membranes (Fig. 4C and D) is a remarkable ﬁnding. Since the
immunoblots are from total membranes, including both plasma and
internal membranes, we do not know whether pharmacological
LXR activation affects redistribution of SR-B1 to external mem-
branes. This can be an area for further study. SR-B1 membrane
protein stability is regulated in a complex and not well-understood
fashion, although PDZK1 is known to play an important role herein
[18,19]. However, membranous PDZK1 proteins were not reduced
(Fig. 4C). It has been reported that cholesterol feeding reduced
hepatic SR-B1 proteins in a sterol-regulatory element-binding
protein-1c (SREBP-1c)-dependent fashion in mice [29]. Since LXR
is a main regulator of SREBP-1c transcriptional activity [30], the
LXR-SREBP-1c pathway might regulate SR-B1 membrane stability.
Strikingly, a lower band appeared in the SR-B1 immunoblot of hep-
atic membranes upon LXR activation. This lower band might be the
unglycosylated form of SR-B1 as previously reported [31], but this
requires more investigation.
Our data show that SR-B1-mediated hepatic HDL
cholesterylester uptake only had a minor, if any, contribution
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Fig. 5. Elevated plasma cholesterol and fecal neutral sterol secretion upon pharmacological LXR activation do not require SR-B1. A. Cholesterol FPLC proﬁles of untreated
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rr-b1−/− mice and Sr-b1−/− mice treated with the pharmacological LXR ligand T090
-C.  The 24-h fecal neutral sterol (B) and bile acid (C) secretion of untreated Sr-b1
 weeks. Values are averages ± SD; n = 6; *P < 0.05 vs. untreated mice.
o LXR-mediated fecal neutral sterol secretion since treatment of
r-b1−/− mice with T0901317 induced fecal neutral sterol secretion
s strong as in wild-type mice (Fig. 5B). This underscores that
he HDL-to-feces cholesterol ﬂux is of only minor importance in
XR-induced whole-body cholesterol removal. Indeed, TICE has
een shown not to be decreased but to be even increased in Sr-b1
eﬁcient mice [25].
With respect to the effects of pharmacological LXR activation
n plasma HDL-cholesterol concentrations, our studies for the ﬁrst
ime report that not only the induction of the classical reverse
holesterol transport (mediated by ABCA1 and ABCG1) but also
educed HDL cholesterol uptake (mediated by SR-B1) might be
nvolved in induced plasma HDL cholesterol upon T0901317 treat-
ent in mice. Plosch et al. [22] reported a 26% reduction of Sr-b1
ene expression in mice on the DBA1 background upon T0901317
reatment, but no signiﬁcant reduction in Sr-b1 in Abca1 deﬁcient
ice on the same background. The difference of the T0901317
reatment on the Sr-b1 expression between this [22] and our study
Fig. 4A) might be due to the background. There are differences in
he backgrounds of the various knockout models we use, but since
nockouts were compared with their wild-type littermates, we  are
ble to draw conclusions about the involvement of either LXR or
R-B1 in pharmacological LXR activation. In line with our obser-
ations, Plosch et al. also showed that T0901317 enhanced fecal
terol secretion in both wild-type and the Abca1 deﬁcient mice [22].
t might be of interest to investigate the effects of pharmacologi-
al LXR activation on fecal cholesterol secretion in the Abca1/Sr-b1
ouble knockout mice.
Altogether, the data show that LXR activation unexpectedly
educed SR-B1 protein in hepatic membranes, an effect that mightfor 2 weeks. Inset: Area under the curve (AUC) of the cholesterol vs. fraction curve.
ice and Sr-b1−/− mice treated with the pharmacological LXR ligand T0901317 for
explain in part the increased concentration of HDL cholesterol and
the larger size of the HDL particles. In addition, SR-B1 is clearly
not required for the T0901317-mediated induction of whole body
cholesterol removal via the feces.
Acknowledgement
The authors would like to thank Rick Havinga and Renze Bover-
hof for their skilful technical assistance.
References
[1] Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol
signalling pathway mediated by the nuclear receptor LXR alpha. Nature
1996;383:728–31.
[2] Willy PJ, Umesono K, Ong ES, Evans RM,  Heyman RA, Mangelsdorf DJ. LXR, a
nuclear receptor that deﬁnes a distinct retinoid response pathway. Genes Dev
1995;9:1033–45.
[3]  Teboul M,  Enmark E, Li Q, Wikstrom AC, Pelto-Huikko M,  Gustafsson JA. OR-1,
a  member of the nuclear receptor superfamily that interacts with the 9-cis-
retinoic acid receptor. Proc Natl Acad Sci U S A 1995;92:2096–100.
[4] Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control
of  cellular lipid homeostasis and beyond. Implications for drug design. Prog
Lipid Res 2010;49:343–52.
[5] van der Veen JN, van Dijk TH, Vrins CL, et al. Activation of the liver X recep-
tor  stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem
2009;284:19211–9.
[6] van der Velde AE, Brufau G, Groen AK. Transintestinal cholesterol efﬂux. Curr
Opin Lipidol 2010;21:167–71.
[7] Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by
pharmacological activation of the liver X receptor leads to production of
large, triglyceride-rich very low density lipoprotein particles. J Biol Chem
2002;277:34182–90.
[8] Jiang XC, Beyer TP, Li Z, et al. Enlargement of high density lipoprotein
in mice via liver X receptor activation requires apolipoprotein E and is
osclero
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[A. Grefhorst et al. / Ather
abolished by cholesteryl ester transfer protein expression. J Biol Chem
2003;278:49072–8.
[9] Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by
liver X receptors in vivo. J Biol Chem 2002;277:39561–5.
10] Rigotti A, Trigatti BL, Penman M,  Rayburn H, Herz J, Krieger M.  A targeted muta-
tion in the murine gene encoding the high density lipoprotein (HDL) receptor
scavenger receptor class B type I reveals its key role in HDL metabolism. Proc
Natl Acad Sci U S A 1997;94:12610–5.
11] van der Veen JN, Havinga R, Bloks VW,  Groen AK, Kuipers F. Cholesterol feeding
strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver
X  receptor alpha. J Lipid Res 2007;48:337–47.
12] Brufau G, Kuipers F, Lin Y, Trautwein EA, Groen AK. A reappraisal of the mech-
anism by which plant sterols promote neutral sterol loss in mice. PLoS One
2011;6:e21576.
13] Murphy GM,  Billing BH, Baron DN. A ﬂuorimetric and enzymatic method for
the  estimation of serum total bile acids. J Clin Pathol 1970;23:594–8.
14] Wiersma H, Nijstad N, Gautier T, et al. Scavenger receptor BI facilitates hep-
atic  very low density lipoprotein production in mice. J Lipid Res 2010;51:
544–53.
15] Hulzebos CV, Renfurm L, Bandsma RH, et al. Measurement of parameters of
cholic acid kinetics in plasma using a microscale stable isotope dilution tech-
nique: application to rodents and humans. J Lipid Res 2001;42:1923–9.
16] Engelking LJ, Kuriyama H, Hammer RE, et al. Overexpression of Insig-1 in
the  livers of transgenic mice inhibits SREBP processing and reduces insulin-
stimulated lipogenesis. J Clin Invest 2004;113:1168–75.
17] Koopen NR, Wolters H, Voshol P, et al. Decreased Na+-dependent taurocholate
uptake and low expression of the sinusoidal Na+-taurocholate cotransport-
ing  protein (Ntcp) in livers of mdr2 P-glycoprotein-deﬁcient mice. J Hepatol
1999;30:14–21.
18] Fenske SA, Yesilaltay A, Pal R, et al. Normal hepatic cell surface localiza-
tion of the high density lipoprotein receptor, scavenger receptor class B,
type I, depends on all four PDZ domains of PDZK1. J Biol Chem 2009;284:
5797–806.
19] Yesilaltay A, Kocher O, Pal R, et al. PDZK1 is required for maintaining hepatic
scavenger receptor, class B, type I (SR-BI) steady state levels but not its surface
localization or function. J Biol Chem 2006;281:28975–80.
[sis 222 (2012) 382– 389 389
20] Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M.  Targeted disruption
of the PDZK1 gene in mice causes tissue-speciﬁc depletion of the high density
lipoprotein receptor scavenger receptor class B type I and altered lipoprotein
metabolism. J Biol Chem 2003;278:52820–5.
21] Trigatti B, Rigotti A, Krieger M.  The role of the high-density lipoprotein receptor
SR-BI in cholesterol metabolism. Curr Opin Lipidol 2000;11:123–31.
22] Plosch T, Kok T, Bloks VW,  et al. Increased hepatobiliary and fecal cholesterol
excretion upon activation of the liver X receptor is independent of ABCA1. J Biol
Chem 2002;277:33870–7.
23] Huuskonen J, Olkkonen VM,  Jauhiainen M,  Ehnholm C. The impact of
phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis
2001;55:269–81.
24] Rye K-A, Clay M,  Barter PJ. Remodelling of high density lipoproteins by plasma
factors. Atherosclerosis 1999;145:227–38.
25] van der Velde AE, Vrins CL, van den Oever K, et al. Regulation of direct transin-
testinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol
2008;295:G203–8.
26] Kruit JK, Plosch T, Havinga R, et al. Increased fecal neutral sterol loss upon
liver  X receptor activation is independent of biliary sterol secretion in mice.
Gastroenterology 2005;128:147–56.
27] Lo Sasso G, Murzilli S, Salvatore L, et al. Intestinal speciﬁc LXR activation stim-
ulates reverse cholesterol transport and protects from atherosclerosis. Cell
Metab 2010;12:187–93.
28] Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev
2000;14:2831–8.
29] Niemeier A, Kovacs WJ,  Strobl W,  Stangl H. Atherogenic diet leads to
posttranslational down-regulation of murine hepatocyte SR-BI expression.
Atherosclerosis 2009;202:169–75.
30] Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished
hepatic response to fasting/refeeding and liver X receptor agonists in mice
with selective deﬁciency of sterol regulatory element-binding protein-1c. J Biol
Chem 2002;277:9520–8.
31] Voshol PJ, Schwarz M,  Rigotti A, Krieger M,  Groen AK, Kuipers F. Down-
regulation of intestinal scavenger receptor class B, type I (SR-BI) expression
in rodents under conditions of deﬁcient bile delivery to the intestine. Biochem
J  2001;356:317–25.
